Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

AXA Framlington Biotech Fund GBP Z Acc

Performance History31/10/2019
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech Fund GBP Z Acc
Fund12.3-4.99.7-6.48.6
+/-Cat-1.1-1.0-0.61.50.2
+/-B’mrk-5.91.2-1.4-3.2-0.8
 
Category: Sector Equity Biotechnology
Category Benchmark: NASDAQ Biotechnology TR USD
Key Stats
NAV
15/11/2019		 GBX 328.80
Day Change -1.29%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB00B784NS11
Fund Size (Mil)
31/10/2019		 GBP 365.27
Share Class Size (Mil)
15/11/2019		 GBP 253.44
Max Initial Charge -
Ongoing Charge
07/08/2019		  0.83%
Investment Objective: AXA Framlington Biotech Fund GBP Z Acc
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.
Returns
Trailing Returns (GBP)15/11/2019
YTD10.48
3 Years Annualised2.37
5 Years Annualised5.02
10 Years Annualised*16.33
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
16/04/2012
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech Fund GBP Z Acc31/10/2019
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock96.720.0096.72
Bond0.000.000.00
Property0.000.000.00
Cash2.040.091.95
Other1.330.001.33
Top 5 Regions%
United States85.26
Eurozone5.23
Europe - ex Euro3.94
Asia - Emerging2.12
Japan2.03
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Amgen IncHealthcareHealthcare8.90
Biogen IncHealthcareHealthcare7.81
Alexion Pharmaceuticals IncHealthcareHealthcare6.39
Gilead Sciences IncHealthcareHealthcare6.26
Biomarin Pharmaceutical IncHealthcareHealthcare4.26
Increase Decrease New since last portfolio
AXA Framlington Biotech Fund GBP Z Acc
* This share class has performance data calculated prior to the inception date, 2012-04-16. This is based upon a simulated/extended track record, using the track record of AXA Framlington Biotech R Acc (ISIN: GB0031007254), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.
  • Other Morningstar Websites
© Copyright 2018 Morningstar, Inc. All rights reserved.      Terms of Use     Privacy Policy.    Cookie Consent
HelpGlossaryLicensing OpportunitiesData OpportunitiesCareersContact MorningstarMethodologyAdvertiseSite MapCookie Consent
© Copyright 2019 Morningstar. All rights reserved. Terms of Use | Privacy Policy | Cookies

The Morningstar Star Rating for Stocks is assigned based on an analyst's estimate of a stocks fair value. It is projection/opinion and not a statement of fact. Morningstar assigns star ratings based on an analyst’s estimate of a stock's fair value. Four components drive the Star Rating: (1) our assessment of the firm’s economic moat, (2) our estimate of the stock’s fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process culminates in a single-point star rating that is updated daily. A 5-star represents a belief that the stock is a good value at its current price; a 1-star stock isn't. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Morningstar Star Rating for Stocks, please visit here

Quantitative Fair Value Estimate represents Morningstar’s estimate of the per share dollar amount that a company’s equity is worth today. The Quantitative Fair Value Estimate is based on a statistical model derived from the Fair Value Estimate Morningstar’s equity analysts assign to companies which includes a financial forecast of the company. The Quantitative Fair Value Estimate is calculated daily. It is a projection/opinion and not a statement of fact. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Quantiative Fair Value Estimate, please visit here